INSYS Therapeutics (INSY) Stock Price, News & Analysis

Company Overview

Insys Therapeutics, Inc., a specialty pharmaceutical company, focuses on cannabinoids and drug delivery systems that address unmet patient needs. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. It also develops Cannabidiol Oral Solution, a synthetic cannabidiol, for the treatment of rare childhood epilepsy syndromes that include west syndrome and childhood absence epilepsy, as well as glioblastoma multiforme, pontine glioma, and pediatric schizophrenia. In addition, the company develops Buprenorphine Sublingual Spray for acute pain; Epinephrine Nasal Spray for allergic reactions, including anaphylaxis; and Naloxone Nasal Spray for opioid antagonist. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.23 to $65,799,000.00
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 9.52 million shs
• Market Capitalization: $21.71 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

INSY Stock Analysis - Frequently Asked Questions

How were INSYS Therapeutics' earnings last quarter?

INSYS Therapeutics, Inc. (NASDAQ:INSY) released its earnings results on Friday, May, 10th. The specialty pharmaceutical company reported ($0.55) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by $0.33. The firm's quarterly revenue was down 68.1% compared to the same quarter last year.

When did INSYS Therapeutics' stock split?

Shares of INSYS Therapeutics split before market open on Monday, March 31st 2014. The 3-2 split was announced on Tuesday, March 4th 2014. The newly created shares were distributed to shareholders after the market closes on Friday, March 28th 2014. An investor that had 100 shares of stock prior to the split would have 150 shares after the split.

What other stocks do shareholders of INSYS Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that INSYS Therapeutics investors own include Cara Therapeutics (CARA), GW Pharmaceuticals (GWPH), Puma Biotechnology (PBYI), Zynerba Pharmaceuticals (ZYNE), Canopy Growth (CGC), Incyte (INCY) and BioMarin Pharmaceutical (BMRN).

Company Calendar

• Last Earnings: 5/10/2019
• Today: 2/22/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:INSY
• Previous Symbol: NASDAQ:NEOL
• CUSIP: N/A
• CIK: 1516479
• Web: www.insysrx.com
• Phone: 480-500-3127
• Fax: N/A
• Employees: 226
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.39)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-124,510,000.00
• Net Margins: -346.61%
• Pretax Margin: N/A
• Return on Equity: -1,430.37%
• Return on Assets: -64.04%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.54
• Quick Ratio: 0.50

Sales & Book Value

• Annual Sales: $82.08 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.58) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 74,570,000
• Free Float: N/A
• Market Cap: $21.71 million
• Optionable: Optionable
• Beta: 3.21